等待开盘 05-18 09:30:00 美东时间
+0.030
+0.97%
Cyclerion Therapeutics (NASDAQ:CYCN) reported quarterly losses of $(0.76) per share. This is a 35.71 percent decrease over losses of $(0.56) per share from the same period last year.
05-13 05:32
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. S...
04-10 03:30
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) shares rose 307.1% to $6.31 durin...
04-02 01:06
BUZZ-Cyclerion soars on merger deal with Korsana Updates ** Shares of biotech firm Cyclerion Therapeutics CYCN.O soar nearly threefold to $ 4.83 in premarket trading ** Co says it will merge with private firm Korsana Biosciences and focus on treatments for Alzheimer's , a n eurodegenerative disorder
04-01 21:16
BUZZ-U.S. STOCKS ON THE MOVE-Seagate, nCino, Zymeworks Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 April 1 (Reuters) - U.S. stock futures rose on Wednesday, after the indexes
04-01 19:40
Cyclerion Therapeutics shares are trading higher after the company announced it...
04-01 19:28
BRIEF-Cyclerion Therapeutics And Korsana Biosciences Announce Merger Agreement April 1 (Reuters) - Cyclerion Therapeutics Inc CYCN.O : CYCLERION THERAPEUTICS AND KORSANA BIOSCIENCES ANNOUNCE MERGER AGREEMENT CO AND KORSANA ANNOUNCE DEFINITIVE ALL-STOCK MERGER AGREEMENT KORSANA SECURES PRIVATE INVEST
04-01 19:14
Cyclerion agrees all-stock merger with Korsana, to rename and trade as KRSA Cyclerion entered a definitive all-stock merger agreement with privately held Korsana Biosciences. Combined company plans to operate as Korsana Biosciences, trading on Nasdaq under ticker KRSA. Korsana secured commitments fo
04-01 19:06
• Eli Lilly to acquire Centessa Pharmaceuticals for up to $7.8 billion. • Acquisition expands neuroscience portfolio into sleep-wake disorders. • Analysts maintain "Buy" ratings with substantial upside price targets.
04-01 14:15
Cyclerion Therapeutics has received positive regulatory feedback from the FDA for its Phase 2 POC study of CYC-126 for treatment-resistant depression (TRD). CYC-126, an anesthetic-based therapy using real-time EEG feedback, aims to address TRD through individualized, precision delivery. The FDA supports the study design, leveraging approved anesthetics, allowing Cyclerion to remain on track to initiate the trial in late 2026. Additionally, the co...
02-17 12:00